Table 2 Response to pre-emptive CMV therapy
All (n = 61) | Valacyclovir (n = 15) | Valganciclovir (n = 16) | Foscarnet (n = 30) | P | |
|---|---|---|---|---|---|
Median time to antigenemia (days from transplant, range) | 27 (12–387) | 39 (16–387) | 31.5 (15–119) | 24.5 (12–104) | 0.084 |
Median viral load (No. of CMV positive cells per million leukocytes, range) | 3 (1–750) | 3 (1–40) | 3 (2–181) | 3.5 (1–750) | 0.772 |
Clearance, N (%) | 60 (98.1) | 15 (100) | 16 (100) | 29 (96.7) | 0.591 |
Recurrent antigenemia, N (%) | 34 (55.8) | 7 (46.7) | 11 (68.8) | 16 (53.3) | 0.434 |
Median days to recurrence | 43.5 (11–173) | 59 (27–173) | 42 (14–94) | 38 (11–163) | 0.081 |